Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Generate Biomedicines, Inc.NASDAQ: GENB

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax of -$61.69M in Q1 FY2026

Q1 FY2026 income before tax was -$61.69M.

Context

  • Income before tax amounted to 698.6% of revenue in FY2025, down 186.9 pp from a year earlier.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$61.69M— QoQ
Last fiscal yearDec 2025
-$222.8M-23.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-23.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(222.8M) USD
Year-over-year change
-23.0%

Income Before Tax vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 income before tax of -$222.8M is the lowest of the 5 companies compared; the peer median is -$141.95M.
  • Its year-over-year change of -23.0% is the 4th highest of 5, against a peer median of +3.2%.
  • Income before tax amounts to 698.6% of revenue for GENB, versus a peer median of 3348.8%.
GENB Competitors Peer median
Income Before Tax for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABSIAbsci CorporationLTM Mar 2026-$118.35M -10.2%—6445.8%
INBXInhibrx Biosciences, Inc.LTM Mar 2026-$130.18M -107.6%—10014.1%
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M +36.7%—154.3%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$170.81M +16.6%—251.7%
GENBGenerate Biomedicines, Inc.FY2025-$222.8M -23.0%—698.6%
Peer median (excluding GENB) -$141.95M+3.2%—3348.8%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.46M31.89M
Cost of Revenue00
Gross Profit20.46M31.89M
Gross Margin100.0%100.0%
Research & Development175.31M224.7M
Selling, General & Admin42.09M42.26M
Operating Expenses217.4M266.96M
Depreciation & Amortization15.35M13.18M
EBITDA(163.71M)(208.49M)
EBITDA Margin-800.2%-653.7%
Operating Income(196.94M)(235.07M)
Operating Margin-962.6%-737.0%
Interest Income18.12M13.66M
Interest Expense2.12M1.14M
Other Income / Expenses15.77M12.26M
Income Before Tax(181.17M)(222.8M)
Pre-Tax Margin-885.5%-698.6%
Income Tax Expense212K163K
Net Income(173.77M)(203.15M)
Net Margin-849.4%-637.0%
EPS (Basic)(1.68)(4.98)
EPS (Diluted)(1.68)(4.98)
Weighted Avg Shares127.45M50.09M
Weighted Avg Shares (Diluted)127.45M50.09M

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.